News
Key Points Non-GAAP EPS was ($0.13), missing the consensus estimate by $0.02 (non-GAAP), due to higher pre-commercialization spending. Research and development expenses fell 48.2% compared to Q2 2024, ...
The health department’s Biomedical Advanced Research and Development Authority (BARDA) is “terminating 22 mRNA vaccine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback